Pozen has received a US patent that covers development of new drugs in the pharmaceutical firm’s pipeline.
The patent covers the combination of non-steroidal anti-inflammatory drugs and an acid inhibitor. Pozen (Nasdaq: POZN) said it has such drug combinations under development. They are designed to prevent gastrointestinal complications.
The drugs under development are designed for pain management of conditions such as osteoarthritis, Pozen said.
Pozen: www.Pozen.com
